Remember the ProFax project that involved two students from the Politecnico di Milano? If you don’t, the ProFax project aim to achievement an improvement in performance and power consumption, using the new toolchain di Xilinx: SDAccel, through the board Alpha Data.
Lorenzo e Giulia, with their project, won the Xilinx Open Hardware Contest 2016, in Student FPGA category.
Giulia e Lorenzo arrived at Dublin
Giulia has been appassionate bioinformatics after attending the computer course taugth by Prof. Domenico Marco Santambrogio, responsable of NECSTlab at the Politecnico di Milano. Curiosity led her to know deeper about bioinformatics and then she proposed her idea to Prof Santambrogio, who decided to support her.
Her experience at the NECSTlab led her to add some informatics exams to her Biomedical Engineering course.
Lorenzo, however, was interested in the hardware architectures during his fourth year, also him at the Politecnico di Milano, while he attended the course of High Performance Processor and Systems. During that, he has taken part in a project concerning the hardware acceleration. He also straightened his knowledge about the subject during his internship of six months in the Xilinx Research Laboratories (the company that invented the FPGA) in Dublin, Ireland, under the supervision of Dr. Michaela Blott.
Following the purpose of Giulia, he began to work with her on the implementation, which led to a publication during the RAW conference.
The Xilinx Open Hardware Design Contest offers to students the opportunity to show their technical skills and their creative talents; to enter the contest, any platform provided from the Xilinx can be used.
On 24 and 25 of August, Giulia and Lorenzo flew to Dublin, the European headquarters of the organizer, the Xilinx, for a final presentation of their work, as well as a DEMO and to attend the final award ceremony.
Giulia e Lorenzo with Kevin Cooney – Corporate Vice President & Managing Director EMEA & Global Chief Information Officer at Xilinx (from the left) e Patrick Lysaght – Senior Director at Xilinx
“It has been a great moment, we have been repaid of the hard work and the commitment of the last months.”
said the two winners
“Knowing that experts in the field valued so good our work made us very proud.
We would like to thank firstly our adviser, Marco D. Santambrogio, our colleagues and all the NECSTLab at Politecnico di Milano; support and collaboration should always be present in a work environment, where personal growth as a person, more than from a professional point of view, plays a key role. ”
Now, the two students has returned already at work to make improvements and optimizations, and to test some new possible roads; they plan also to develop other projects in the genomic scope, also using Xilinx technologies.
Cinema and TV series often propose as main characters “living cadavers”, even known as zombies, or superheroes able to regenerate any part of their body .
But if this eventuality would be really possible?
Close-up Engineering interviewed Bioquark Inc., the American company that deals with research, study and implementation of biologics targeted to cell regeneration and the real cure of diseases that, until now, can only be soothed, such as Parkinson or Alzheimer.
“Bioquark Inc is an American company founded in 2007, located in Philadelphia, Pennsylvania, and funded by entrepreneurs of the Eastern United States”.
The company is involved in research and implementation of biological drugs with properties of endogenous regeneration and repair of tissues. Exactly, it introduces the concept of epimorphism.
Epimorphism, or epimorphic regeneration, consists in the ability to literally regrow part of a fabric starting from an
“undifferentiated” and causing it to proliferate until reaching the right size; that is, explains Ira, that “the cells may be able to cancel their previous history to become the missing piece”.
“The research program is carried out within the Bioquark” continues to explain Ira “and it is focused on the study of the genome of living beings that have the ability to repair and regenerate entire sections of the brain and brain stem, starting even from serious trauma. We are talking about amphibians, reptiles, fish and small mammals“.
In particular, amphibians are animals with high capacity for regeneration: in fact can revive not only arts, but also spine, liver and parts of the brain.
Even in humans and mammals they have occurred tissue reconstruction phenomena, even if in a more limited form, although recent medical advances have achieved positive results in the regenerative response of the central nervous system.
Methods for testing in order to cope with neurological diseases also include the use of stem cells, but they haven’t yet yielded the expected results, due to many causes such as poor efficiency of transplantation, pathogenic or not enough immune activity.
The aim of the study was to have as ultimate goal the ability to initiate a regenerative response directly from the patient, using its own cells.
For this purpose has been studied as an animal model, the zebrafish, known for its well-known ability to regenerate all parts of the brain.
The results obtained can be of great assistance in understanding the “molecular programs” that stem cells and progenitor follow in order to reconstruct the lost neurons and understand how to study the biology of the central nervous system of vertebrates.
Both in humans and other living beings there is a particular feature of the nervous system: the memory.
We can imagine the brain as a computer: before you change “parts” of a PC you have to save all the information needed in an external memory in order not to lose them.
But “what are the dynamics of memory in the regeneration of the brain?”, Or what happens in small mammals that are able to regenerate brain tissue?
The answer to this argument is still unknown, but it has been hypothesized that there is a more strong structure of the brain that acts as a “backup” storage medium during regeneration.
As already said, the ultimate goal of this research will be to create the possibility of inducing the same tissues in situ, using combinations of soluble molecules and/or regeneration models, although applicants questions on “when it will be possible to regrow a limb” lead vague answers and they do not offer a definite answer.
The cause for which frogs, birds and most mammals are devoid of this capacity could involve the immune system, the loss of regenerators genes or the ability to create inhibitors for regeneration, but everything is still in the research stage and deepening.
THE REANIMA PROJECT
Recently in the Bioquark family was born the ReAnima Project, which involves many experts in medicine and technology, whose common goal is the research on neural and vascular regeneration of subjects in condition of “brain death”. Brain death is defined by the Uniform Determination of Death Act (UDDA) -a law passed in the US in 1981 and adopted by most of the country to “establish comprehensive bases and medical mold for the determination of death in any situation” – and is understood as a complete and irreversible loss of brain function (including involuntary activities).
This definition is used to determine a patient clinically and legally dead, although these inconsistencies: in fact, some parts of the brain can continue to live while others die.
“I always believed that scientific progress happened in a very linear narrative, with each new discovery supporting the next, resulting ultimately in an eventual stairway of scientific enlightenment” – Ira S. Pastor
“To undertake such a complex initiative” explains Ira “we are combining biologic regenerative medicine tools (Bioquark’s reprogramming biologics as well as autologous stem cells), with other existing medical devices typically used for stimulation of the CNS in patients with other severe disorders of consciousness (coma/PVS) such as median nerve stimulation and transcranial IV laser.”
After the IRB approval (Institutional Review Board – an ethical resolution, designated for the approval and monitoring of research involving human beings)for the first
20 subjects of the company “We hope to begin recruiting patients as possible with this first site” tells us the same
Ira “we are working with hospitals to identify families where there is a religious or medical obstacle to organ donation, which can be considered as an alternative this project as a pure search for scientific progress.”
“In the near future” always keeps the managing director, “we hope to complete all projects and to publish important results and significant (in the next 2-3 months), which give way to a second research protocol, which will aim the real cure of neurodegenerative conditions and often fatal diseases, such as coma, Alzheimer’s, Parkinson’s, ALS, MS, and more.“
Trying to go beyond the true meaning of irreversibility, whose definition given by Harvard has been in place since 1968, we must think that we live almost 50 years later and above in a completely different technological age; today we are able to restart with success heartbeat and respiration.
In the US, research on the “living cadaver” has been ongoing for several decades and there have been reports of survivors from brain death, especially in young subjects.
We enclose the Publications link supplied to us by the same Ira, who commented these episodes asserting that “in this field of study is not black or white, but with the suitable technologies is a road that must be tread.”
The Argus II bionic eye converts the sequence of video frames captured by a room miniaturized into a series of electrical impulses that are sent wirelessly to the electrodes on the surface of the retina
AccuVein is a private US that develops products that facilitate the visualization of peripheral vasculature.
AccuVein – AV400 – displays in real-time digital map of the vasculature on the skin surface, allowing doctors to check the patency of the vein and prevent valves and bifurcations. The veins are shown because the hemoglobin in the blood absorbs preferentially light to infrared rays. For this reason, the vascular system displayed represents the contents of the veins and not the entire vein. The AccuVein system is portable and lightweight, weighs only 275gr. Venipuncture is a procedure that requires that both hands are free, then AccuVein is equipped if necessary of supports on wheels or stationary in a position to allow the user to keep the device above the patient’s body and at the same time having full mobility. The design allows the device to be easily cleaned and sterilized. AV400 is aligned permanently. Use is made more easier by the possibility for AccuVein to rotate in any direction above the vein displayed, this makes AV400 useful on a variety of patient types. The accuracy when precision, up to the width of a human hair, allows AccuVein detect veins up to 10 mm depth. The innovation is in response venipuncture procedures more effective and greater satisfaction among patients, which makes it clear why many facilities have chosen to integrate AccuVein in their standard of care.
SYSTEM INCLUDES
AV400 unit including battery
Charging Kit
Universal power supply, and multinational adapters
The device AccuVein reduce 39% pain in cases of venous access difficult – DVA -such as in patients with a BMI of more than 35 . increased of success increased from 50% to 96% marking an important turning point for all those who have a DVA. In the pediatric field the system represents a true revolution. Medical professionals know that venipuncture can be especially difficult in some patients. Among which:
The elderly
Patients with dark skin, in which the veins are not highly visible
Patients Obese, in which the veins can not be visible or palpable
Patients who have many diagnostic or therapeutic procedures intravenously
Burns
Cancer patients in chemotherapy
Addicts
accuvein.com
Not are omitted at this point the advantages from the economic point of view. The cost savings using AccuVein far exceeds the cost of normal needles – about $ 100,000 for each company hospital – if a service of hospitalization were to use AccuVein even once a week, there would be a cost savings of around three times and risk prevention of serious infection would be a further significant benefit. The device is also used by the educational point of view of future doctors, nurses and paramedics during their internship. They say AccuVein:
“In my 29 years of service as a paramedic, this is one of the few times I’ve used a tool that improves the response with patients, reduces the risk of infection and allows cost savings. AccuVein is a real lifesaver. ”
– Paramedic in Birmingham –
“Where is it? We need it! Other departments are jealous that we AccuVein.”
– Children’s Research Hospital, department of anesthesia –
“The patient was surprised, frankly, I too!”
– Medical Director of Vein Clinic –
AccuVein demonstrates again as research and technology is a perfect combination and efficient to assure the protection and welfare of each of us.
